ANI PharmaceuticalsANIP
About: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Employees: 642
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
93% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 44
26% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 31
18.37% more ownership
Funds ownership: 74.47% [Q2] → 92.84% (+18.37%) [Q3]
18% more capital invested
Capital invested by funds: $994M [Q2] → $1.17B (+$177M) [Q3]
3% more funds holding
Funds holding: 201 [Q2] → 207 (+6) [Q3]
9% less call options, than puts
Call options by funds: $721K | Put options by funds: $793K
100% less funds holding in top 10
Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Leerink Partners Faisal Khurshid 30% 1-year accuracy 3 / 10 met price target | 34%upside $80 | Outperform Initiated | 11 Dec 2024 |
HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 23 / 46 met price target | 58%upside $94 | Buy Reiterated | 11 Nov 2024 |
Financial journalist opinion
Based on 6 articles about ANIP published over the past 30 days
